167 related articles for article (PubMed ID: 22895138)
1. Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.
Chaft JE; Sima CS; Ginsberg MS; Huang J; Kris MG; Travis WD; Azzoli CG
J Thorac Oncol; 2012 Sep; 7(9):1400-5. PubMed ID: 22895138
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.
Dy GK; Bogner PN; Tan W; Demmy TL; Farooq A; Chen H; Yendamuri SS; Nwogu CE; Bushunow PW; Gannon J; Adjei AA; Adjei AA; Ramnath N
J Thorac Oncol; 2014 Feb; 9(2):222-30. PubMed ID: 24419420
[TBL] [Abstract][Full Text] [Related]
3. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 expression is a prognostic biomarker for non-small cell lung cancer patients treated with adjuvant platinum-based chemotherapy.
Shimizu K; Yukawa T; Okita R; Saisho S; Maeda A; Nojima Y; Nakata M
World J Surg Oncol; 2015 Feb; 13():21. PubMed ID: 25888998
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis.
Malhotra J; Mhango G; Gomez JE; Smith C; Galsky MD; Strauss GM; Wisnivesky JP
Ann Oncol; 2015 Apr; 26(4):768-773. PubMed ID: 25600562
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
7. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
[TBL] [Abstract][Full Text] [Related]
8. Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt WE; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Griesinger F; Thomas M;
J Thorac Oncol; 2016 Jan; 11(1):85-93. PubMed ID: 26762743
[TBL] [Abstract][Full Text] [Related]
9. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
10. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients.
Dediu M; Ion O; Ion R; Alexandru A; Median D; Gal C; Horvat T; Motas C; Motas N
J BUON; 2012; 17(2):317-22. PubMed ID: 22740212
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study.
Blumenschein GR; Ciuleanu T; Robert F; Groen HJ; Usari T; Ruiz-Garcia A; Tye L; Chao RC; Juhasz E
J Thorac Oncol; 2012 Sep; 7(9):1406-16. PubMed ID: 22743295
[TBL] [Abstract][Full Text] [Related]
12. Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy.
Saji H; Tsuboi M; Matsubayashi J; Miyajima K; Shimada Y; Imai K; Kato Y; Usuda J; Kajiwara N; Uchida O; Ohira T; Hirano T; Mukai K; Kato H; Ikeda N
Anticancer Drugs; 2010 Jan; 21(1):89-93. PubMed ID: 19770636
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer.
Baykara M; Coskun U; Berk V; Ozkan M; Kaplan MA; Benekli M; Karaca H; Inanc M; Isikdogan A; Sevinc A; Elkiran ET; Demirci U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(10):5119-24. PubMed ID: 23244121
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
[TBL] [Abstract][Full Text] [Related]
15. Lung cancer in women, a different disease: survival differences by sex in Turkey.
Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy for non-small cell lung cancer: practice patterns and outcomes in the general population of Ontario, Canada.
Booth CM; Shepherd FA; Peng Y; Darling G; Li G; Kong W; Mackillop WJ
J Thorac Oncol; 2012 Mar; 7(3):559-66. PubMed ID: 22307012
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase II trial of adjuvant chemotherapy with docetaxel plus cisplatin versus paclitaxel plus carboplatin in patients with completely resected non-small cell lung cancer: TORG 0503.
Kubota K; Kunitoh H; Seto T; Shimada N; Tsuboi M; Ohhira T; Okamoto H; Masuda N; Maruyama R; Shibuya M; Watanabe K
Lung Cancer; 2020 Mar; 141():32-36. PubMed ID: 31931444
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
19. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
[TBL] [Abstract][Full Text] [Related]
20. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]